Results 181 to 190 of about 29,527 (256)

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Simultaneous versus Sequential Cessation of Tobacco and Cannabis: Preferences of Young Adults Who Co‐Use in France

Drug and Alcohol Review, Volume 45, Issue 6, September 2026.
ABSTRACT Introduction Co‐use of tobacco and cannabis is common among young adults and is associated with higher dependence and quitting difficulties. Little is known about the preference for simultaneous or sequential dual cessation in this population.
Tangui Barré, Géraldine Cazorla, Vincent Leroy, Gwenaëlle Maradan, Clotilde Couderc, Julia de Ternay, Carlotta Magnani, Patrizia Carrieri   +7 more
wiley   +1 more source

Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. [PDF]

Ther Clin Risk Manag
Pratama R, Muhaimin M, Khairinisa MA, Chaerunisaa AY.   +3 more
europepmc   +1 more source

Potential Iatrogenic Harms From Medicinal Cannabis Prescribing in Australia: A Case Series

Drug and Alcohol Review, Volume 45, Issue 6, September 2026.
ABSTRACT Introduction Medicinal cannabis prescribing in Australia has increased markedly, including for psychiatric indications where evidence of benefit is limited and of low certainty. The rise of highly commercialised prescribing models has raised concerns regarding patient safety, particularly for those with pre‐existing psychiatric or addiction ...
Richard Bradlow, James Sorensen, Anna Cunningham, Sean Daugherty, Eric Hadinata, Ferghal Armstrong, Nazila Jamshidi   +6 more
wiley   +1 more source

Plasma and urinary exposure of cannabidiol and cannabidiolic acid in horses following consumption of contaminated feed. [PDF]

Ir Vet J
Ekstrand C, Michanek P, Hernlund E, Gehring R, Salomonsson M.   +4 more
europepmc   +1 more source

Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 8, Page 1730-1740, September 2026.
Abstract Objective To assess weight loss with atogepant 60 mg once daily during long‐term treatment of chronic migraine (CM) and episodic migraine (EM) among participants previously failed by two to four classes of conventional oral preventive medications.
Dale S. Bond, Jonathan H. Smith, Alexandra Sinclair, Peter J. Goadsby, Jessica Ailani, Yingyi Liu, Rosa De Abreu Ferreira, Brett Dabruzzo, Joel M. Trugman, B. Lee Peterlin   +9 more
wiley   +1 more source

Sustained Tear Film Exposure After Parenteral Cefovecin Administration in Dogs: Pharmacokinetics and Relevance to Canine Bacterial Keratitis

Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.
ABSTRACT Objective To characterize the tear film pharmacokinetics of parenterally administered cefovecin (Convenia) and compare tear concentrations with the minimum inhibitory concentrations (MICs) of common ocular pathogens. Animals Studied Six healthy research‐bred Beagles.
Meredith R. McClure, Lionel Sebbag, David J. Borts, Rachel A. Allbaugh, Jessica L. Payne, Melissa A. Kubai   +5 more
wiley   +1 more source

Effect of Cannabinoids use on Symptoms of Restless Leg Syndrome among Adults: A Scoping Review. [PDF]

Ann Indian Acad Neurol
Saha S, Tripathi R, Saini LK, Kumar N, Gupta R.   +4 more
europepmc   +1 more source

N‐Arachidonoyl‐phosphatidylethanolamide phospholipase D activation by muscarinic receptors

The Journal of Physiology, Volume 604, Issue 18, Page 7721-7738, 15 September 2026.
Abstract figure legend Activating muscarinic M3 receptors activates Gq‐pathway signalling, including the activation of phospholipase C (PLC) and release of calcium from internal stores as shown in the upper panel. It remains unclear whether the calcium acts on N‐arachidonoyl‐phosphatidylethanolamide phospholipase D (NAPE‐PLD) itself or upstream at N ...
Natalia Murataeva, Connor Schmitt, Elyssa Hyman, Jim Wager‐Miller, Irene Matthews, Ruyi Cai, Shangxuan Cai, Yulong Li, Ken Mackie, Alex Straiker   +9 more
wiley   +1 more source

Cannabis-Based Nanolipid Formulations for Pain Management. [PDF]

Pharmaceutics
Bastos ACS, Sato AO, Oliveira LC, Raffin FN, Moura TFAL, Ferreira LS, Navarro MV, Ribeiro LNM.   +7 more
europepmc   +1 more source